MINTH GROUP(00425) signs development commission service agreement and strategic cooperation agreement with EHang to research and develop and carry out low-altitude aircraft related business.
Minshi Group (00425) announced that on July 7, 2025, Minyi (an indirectly wholly-owned subsidiary of the Company) entered into a development commissioning service agreement with Yihang...
The Minth Group (00425) announced that on July 7, 2025, Minyi (an indirectly wholly-owned subsidiary of the company) entered into a development commission service agreement with Ehang, under which Minyi will provide design, development, manufacturing, and assembly of specified components for low-altitude aircraft to Ehang. On July 21, 2025, Minshi Auto Research (an indirectly wholly-owned subsidiary of the company) entered into a strategic cooperation agreement with Ehang, under which both parties agreed to cooperate in joint research and engage in business related to low-altitude aircraft.
The rise of the global low-altitude economy is accelerating industrial transformation, and the trillion-dollar market is giving birth to new intelligent aviation formats. The low-altitude aircraft industry, as an important carrier of new production forces, has entered the initial stage of large-scale commercial application. The automotive industry and the low-altitude industry have a high degree of synergy and industrial interoperability in manufacturing processes, components, etc. The group is a global top 100 automotive parts enterprise with manufacturing layouts in 14 countries worldwide. In 2023, it made forward-looking arrangements for low-altitude aircraft component projects and gradually established a competitive advantage in body systems and rotor systems components. Ehang is a leader in the global urban air transportation industry. The strategic cooperation between the group and Ehang forms a complementary advantage for both parties and will work together to create a strategic cooperation system for the full value chain of the low-altitude economy, presenting outstanding solutions for the global low-altitude economic transformation.
Related Articles

Di Che Pharmaceutical (688192.SH): Shuo Zhe and Gao Rui Zhe multiple research results selected for the 2025 World Lung Cancer Conference.

Nanning Baling Technology (002592.SZ) plans to launch the second phase of the stock option incentive plan.

Subsidiary YKYY029 injection of Youcare Pharmaceutical Group (688658.SH) has obtained FDA clinical trial approval.
Di Che Pharmaceutical (688192.SH): Shuo Zhe and Gao Rui Zhe multiple research results selected for the 2025 World Lung Cancer Conference.

Nanning Baling Technology (002592.SZ) plans to launch the second phase of the stock option incentive plan.

Subsidiary YKYY029 injection of Youcare Pharmaceutical Group (688658.SH) has obtained FDA clinical trial approval.

RECOMMEND

Backed by BYD, Why Has the Leading EV Charger Firm Seen Revenue Declines and Surging Losses?
23/07/2025

Just Days Away from Losing Tens of Millions of Dollars! Copper-Laden Ships Race Toward U.S. Ports
23/07/2025

Japan "Surrenders"? Trump Claims "U.S. and Japan Reach Deal: Japan Accepts 15% Tariff Rate, Opens Auto and Rice Markets, Pledges $550 Billion in U.S. Investments"
23/07/2025